|LETTER TO EDITOR
|Year : 2019 | Volume
| Issue : 1 | Page : 76-77
Community-acquired Pseudomonas aeruginosa pneumonia in a previously healthy young woman
Abdullah Simsek1, Mesiha Babalık1, Gülay Çekiç Mor2
1 Department of Chest Diseases, Prof. Dr. Türkan Akyol Chest Diseases Hospital, Bursa, Turkey
2 Department of Infectious Diseases and Clinical Microbiology, Prof. Dr. Türkan Akyol Chest Diseases Hospital, Bursa, Turkey
|Date of Submission||25-Apr-2018|
|Date of Decision||22-Jul-2018|
|Date of Acceptance||22-Jul-2018|
|Date of Web Publication||30-Apr-2019|
Dr. Abdullah Simsek
Department of Chest Diseases, Prof. Dr. Türkan Akyol Chest Diseases Hospital, Bursa
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Simsek A, Babalık M, Mor G&. Community-acquired Pseudomonas aeruginosa pneumonia in a previously healthy young woman. Eurasian J Pulmonol 2019;21:76-7
To the Editor,
Pseudomonas aeruginosa is a rare cause of community-acquired pneumonia (CAP) in an immunocompetent host. P. aeruginosa CAP is prone to develop septicemia, is often rapidly progressive., Mortality may be as high as 50%. This report describes a case of P. aeruginosa CAP in a previously healthy woman.
A previously healthy 27-year-old-woman, a nonsmoker referred to our hospital with a 4-day history of cough, high fever, and dyspnea.
A pulmonary physical examination indicated the following: temperature, 38.5 C; blood pressure, 140/80 mmHg; pulse rate, 138 beats/min; and a respiratory rate of 44 breaths/min. Blood oxygen saturation level was 88%. A pulmonary physical examination revealed rales at the right lung. Chest radiograph indicated heterogeneous and homogeneous density in the all zones of the right lung. The initial abnormal serum laboratory findings were as follows: Hgb: 10.4 and elevated C-reactive protein at 201, 5 mg/L. She was admitted to the intensive care unit.
Moxifloxacin treatment was started empirically. Radiologic and clinical response was partial with this treatment. P. aeruginosa was isolated in the sputum. Blood cultures were negative. Antibiotherapy was changed to imipenem-cilastatin due to antibiogram, and the patient developed dramatic clinical, radiological, and laboratory response to this therapy.
P. aeruginosa is frequently found in soil, water, plants, and moist environments. Henderson et al. suggested that P. aeruginosa CAP should be suspected in any patient who has environmental risk factors and has Gram-negative bacilli seen on the Gram stain of the sputum sample, and who presents with pneumonia with overwhelming sepsis.
Any lobe of the lung can be involved, but two-thirds of the patients experience involvement of the right upper lobe.,
Initial empirical antibiotic treatment decision is controversial in previously healthy patients. Sibila et al. suggested that patients who received antipseudomonal antimicrobials within the first 48 h of admission were more likely to survive at 30 days.
A physician should consider P. aeruginosa CAP in previously healthy individuals with critical clinical conditions and with right upper lobe infiltrations in the lung. It would be better to start empirical antimicrobial treatment against P. aeruginosa initially.
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Hatchette TF, Gupta R, Marrie TJ. Pseudomonas aeruginosa
community-acquired pneumonia in previously healthy adults: Case report and review of the literature. Clin Infect Dis 2000;31:1349-56.
Kıraklı C, Koca H, Uçar ZZ, Erbaycu AE, Özacar R. Fatal progression of Pseudomonas aeruginosa
pneumonia in a health care worker. Turk Toraks Der 2010;11:134-7.
Sibila O, Laserna E, Maselli DJ, Fernandez JF, Mortensen EM, Anzueto A, et al.
Risk factors and antibiotic therapy in P. aeruginosa
community-acquired pneumonia. Respirology 2015;20:660-6.
Henderson A, Kelly W, Wright M. Fulminant primary Pseudomonas aeruginosa
pneumonia and septicaemia in previously well adults. Intensive Care Med 1992;18:430-2.
Tsuji S, Saraya T, Tanaka Y, Makino H, Yonetani S, Araki K, et al
. Community-acquired Pseudomonas aeruginosa
pneumonia in previously healthy patients. JMMCR 2014;10:1-5.